A profile of azetukalner for the treatment of epilepsy: from pharmacology to potential for therapy

References

• Hirtz D, Thurman DJ, Gwinn-Hardy K, et al. How common are the “common” neurologic disorders? Neurology. 2007;68(5):326–337. doi: 10.1212/01.wnl.0000252807.38124.a3
   PubMed Web of Science ®Google Scholar
• Asadi-Pooya AA, Brigo F, Lattanzi S, et al. Adult epilepsy. Lancet. 2023;402(10399):412–424. doi: 10.1016/S0140-6736(23)01048-6
   PubMed Web of Science ®Google Scholar
• Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020;168:107966. doi: 10.1016/j.neuropharm.2020.107966
   PubMed Web of Science ®Google Scholar
• Cockerell OC, Johnson AL, Sander JW, et al. Remission of epilepsy: results from the national general practice study of epilepsy. Lancet. 1995;346(8968):140–144. doi: 10.1016/S0140-6736(95)91208-8
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Cagnetti C, Foschi N, et al. Lacosamide monotherapy for partial onset seizures. Seizure. 2015;27:71–74. doi: 10.1016/j.seizure.2015.03.003
   PubMed Web of Science ®Google Scholar
• Chen Z, Brodie MJ, Liew D, et al. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279–286. doi: 10.1001/jamaneurol.2017.3949
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Trinka E, Zaccara G, et al. Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis. Drugs. 2022;82(2):199–218. doi: 10.1007/s40265-021-01661-4
   PubMed Web of Science ®Google Scholar
• Josephson CB, Patten SB, Bulloch A, et al. The impact of seizures on epilepsy outcomes: a national, community-based survey. Epilepsia. 2017;58(5):764–771. doi: 10.1111/epi.13723
   PubMed Web of Science ®Google Scholar
• Laxer KD, Trinka E, Hirsch LJ, et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav. 2014;37:59–70. doi: 10.1016/j.yebeh.2014.05.031
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the thirteenth eilat conference on new antiepileptic drugs and devices (EILAT XIII). Epilepsia. 2017;58(2):181–221. doi: 10.1111/epi.13634
   PubMed Web of Science ®Google Scholar
• Szelenyi I. Flupirtine, a re-discovered drug, revisited. Inflamm Res. 2013;62(3):251–258. doi: 10.1007/s00011-013-0592-5
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Withdrawal of pain medicine flupirtine endorsed. [cited 2023 Mar]. Available from: https://www.ema.europa.eu/en/news/withdrawal-pain-medicine-flupirtine-endorsed
   Google Scholar
• Bialer M, Johannessen SI, Koepp MJ, et al. Progress report on new antiepileptic drugs: a summary of the fourteenth eilat conference on new antiepileptic drugs and devices (EILAT XIV). I. Drugs in preclinical and early clinical development. Epilepsia. 2018;59(10):1811–1841. doi: 10.1111/epi.14557
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Koepp MJ, et al. Progress report on new antiepileptic drugs: a summary of the fifteenth eilat conference on new antiepileptic drugs and devices (EILAT XV). I. Drugs in preclinical and early clinical development. Epilepsia. 2020;61:2340–2364. doi: 10.1111/epi.16725
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Koepp MJ, et al. Progress report on new antiepileptic drugs: a summary of the sixteenth eilat conference on new antiepileptic drugs and devices (EILAT XVI): II. Drugs in more advanced clinical development. Drugs in more advanced clinical development. Epilepsia. 2022;63(11):2883–2910. doi: 10.1111/epi.17376
   PubMed Web of Science ®Google Scholar
• Wang T, Krausss GL. XEN1101: a novel potassium channel modulator for the Potential Treatment of Focal Epilepsy in adults. Touchreviews In Neurology. 2022;18:2–4. doi: 10.17925/USN.2022.18.1.2
   Google Scholar
• Premoli I, Rossini PG, Goldberg PY, et al. TMS as a pharmacodynamic indicator of cortical activity of a novel anti-epileptic drug, XEN1101. Ann Clin Transl Neurol. 2019;6(11):2164–2174. doi: 10.1002/acn3.50896
   PubMed Web of Science ®Google Scholar
• Premoli I, Biondi A, Carlesso S, et al. Lamotrigine and levetiracetam exert a similar modulation of TMS‐evoked EEG potentials. Epilepsia. 2017;58(1):42–50. doi: 10.1111/epi.13599
   PubMed Web of Science ®Google Scholar
• Darmani G, Bergmann TO, Zipser C, et al. Effects of antiepileptic drugs on cortical excitability in humans: a TMS-EMG and TMS-EEG study. Hum Brain Mapp. 2019;40(4):1276–1289. doi: 10.1002/hbm.24448
   PubMed Web of Science ®Google Scholar
• Ossemann M, de Fays K, Bihin B, et al. Effect of a single dose of retigabine in cortical excitability parameters: a cross‐over, double‐blind placebo‐controlled TMS study. Epilepsy Res. 2016;126:78–82. doi: 10.1016/j.eplepsyres.2016.06.004
   PubMed Web of Science ®Google Scholar
• Biondi A, Rocchi L, Santoro V, et al. Spontaneous and TMS-related EEG changes as new biomarkers to measure anti-epileptic drug effects. Sci Rep. 2022;12(1):1919. doi: 10.1038/s41598-022-05179-x
   PubMed Web of Science ®Google Scholar
• French JA, Porter RJ, Perucca E, et al. X-TOLE study group. Efficacy and Safety of XEN1101, a novel potassium channel Opener, in adults with focal epilepsy: a phase 2b randomized clinical trial. JAMA Neurol. 2023;80:1145–1154.
   PubMed Web of Science ®Google Scholar
• Kenney C, French J, Porter R, et al. The impact of disease severity on efficacy from a phase 2b study of XEN1101, a novel potassium channel opener, in adults with focal epilepsy (X-TOLE). Epilepsia. 2022;63(Suppl. 2):136.
   Google Scholar
• French J, Porter R, Perucca E, et al. Interim long-term safety and efficacy of XEN1101, a potent, selective potassium channel Opener: update from an ongoing, open-label extension of a phase 2b study (X-TOLE) in adults with focal epilepsy [abstract 1.277]. In: Presented at: American Epilepsy Society Annual Meeting 2023; Orlando, FL, Dec 1–5, 2023.
   Google Scholar
• French J, Porter R, Perucca E, et al. XEN1101, a novel potassium channel modulator: interim data from an ongoing, long-term, open-label extension of a phase 2B study (X-TOLE) in adults with focal epilepsy [abstract 2.235]. In: Presented at: American Epilepsy Annual Meeting Society 2022; Nashville, TN, Dec 2–6, 2022.
   Google Scholar
• Brandt C, Villanueva V, Harden C, et al. Long-term quality-of-life improvements in adults with focal onset seizures treated with XEN1101 in an ongoing open-label extension of a phase 2b study (X-TOLE) [ abstract 2.260]. Presented at: American Epilepsy Society Annual Meeting 2023; Orlando, FL, Dec 1–5, 2023.
   Google Scholar
• Barrese V, Stott JB, Greenwood IA. KCNQ-encoded potassium channels as therapeutic targets. Annu Rev Pharmacol Toxicol. 2018;58(1):625–648. doi: 10.1146/annurev-pharmtox-010617-052912
   PubMedGoogle Scholar
• Gribkoff VK, Winquist RJ. Potassium channelopathies associated with epilepsy-related syndromes and directions for therapeutic intervention. Biochem Pharmacol. 2023;208:115413. doi: 10.1016/j.bcp.2023.115413
   PubMed Web of Science ®Google Scholar
• Brickel N, Hewett K, Rayner K, et al. Safety of retigabine in adults with partial-onset seizures after long-term exposure: focus on unexpected ophthalmological and dermatological events. Epilepsy Behav. 2020;102:106580. doi: 10.1016/j.yebeh.2019.106580
   PubMed Web of Science ®Google Scholar
• Deckers CLP, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia. 2000;41(11):1364–1374. doi: 10.1111/j.1528-1157.2000.tb00111.x
   PubMed Web of Science ®Google Scholar
• Verrotti A, Lattanzi S, Brigo F, et al. Pharmacodynamic interactions of antiepileptic drugs: from bench to clinical practice. Epilepsy Behav. 2020;104(Pt A):106939. doi: 10.1016/j.yebeh.2020.106939.
   PubMedGoogle Scholar
• Lattanzi S, Canafoglia L, Canevini MP, et al. Adjunctive brivaracetam in focal epilepsy: real-world evidence from the BRIVAracetam add-on first Italian netwoRk STudy (BRIVAFIRST). CNS Drugs. 2021;35(12):1289–1301. doi: 10.1007/s40263-021-00856-3
   PubMed Web of Science ®Google Scholar
• Faught E, Duh MS, Weiner JR, et al. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM study. Neurology. 2008;71(20):1572–1578. doi: 10.1212/01.wnl.0000319693.10338.b9
   PubMed Web of Science ®Google Scholar
• Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav. 2002;3(4):338–342. doi: 10.1016/S1525-5050(02)00037-9
   PubMed Web of Science ®Google Scholar
• Gollwitzer S, Kostev K, Hagge M, et al. Nonadherence to antiepileptic drugs in Germany: a retrospective, population-based study. Neurology. 2016;87(5):466–472. doi: 10.1212/WNL.0000000000002791
   PubMed Web of Science ®Google Scholar
• Fishman J, Kalilani L, Song Y, et al. Antiepileptic drug titration and related health care resource use and costs. J Manag Care Spec Pharm. 2018;24(9):929–938. doi: 10.18553/jmcp.2018.17337
   PubMed Web of Science ®Google Scholar
• Fishman J, Cohen G, Josephson C, et al. Patient emotions and perceptions of antiepileptic drug changes and titration during treatment for epilepsy. Epilepsy Behav. 2017;69:44–52. doi: 10.1016/j.yebeh.2017.01.032
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Ascoli M, Canafoglia L, et al. Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures. Epilepsia. 2022;63(5):e42–50. doi: 10.1111/epi.17223
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Canafoglia L, Canevini MP, et al. Brivaracetam as early add-on treatment in patients with focal seizures: a retrospective, multicenter, real-world study. Neurol Ther. 2022;11(4):1789–1804. doi: 10.1007/s40120-022-00402-3
   PubMed Web of Science ®Google Scholar
• Bjørk MH, Zoega H, Leinonen MK, et al. Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability. JAMA Neurol. 2022;79(7):672–681. doi: 10.1001/jamaneurol.2022.1269
   PubMed Web of Science ®Google Scholar
• Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17(6):530–538. doi: 10.1016/S1474-4422(18)30107-8
   PubMed Web of Science ®Google Scholar
• Cerulli Irelli E, Cocchi E, Morano A, et al. Women with epilepsy treatment options and research (WETOR) study group. Levetiracetam vs Lamotrigine as first-line antiseizure medication in female patients with idiopathic generalized epilepsy. JAMA Neurol. 2023;80(11):1174–1181. doi: 10.1001/jamaneurol.2023.3400
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report. Procedure under article 31 of directive 2001/83/EC resulting from pharmacovigilance data. 2023 [cited 2024 Jan]. Available from: https://www.ema.europa.eu/en/documents/referral/topiramate-article-31-referral-prac-recommends-new-measures-avoid-topiramate-exposure-pregnancy_en.pdf
   Google Scholar
• Kanner AM, Saporta AS, Kim DH, et al. Human epilepsy project. Mood and anxiety disorders and suicidality in patients with newly diagnosed focal epilepsy: an analysis of a complex comorbidity. Neurology. 2023;100(11):e1123–34. doi: 10.1212/WNL.0000000000201671
   PubMed Web of Science ®Google Scholar
• Fiest KM, Dykeman J, Patten SB, et al. Depression in epilepsy: a systematic review and meta-analysis. Neurology. 2013;80(6):590–599. doi: 10.1212/WNL.0b013e31827b1ae0
   PubMed Web of Science ®Google Scholar
• Chen B, Choi H, Hirsch LJ, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2017;76:24–31. doi: 10.1016/j.yebeh.2017.08.039
   PubMed Web of Science ®Google Scholar
• Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf. 2007;30(7):555–567. doi: 10.2165/00002018-200730070-00001
   PubMed Web of Science ®Google Scholar
• Witt JA, Helmstaedter C. How can we overcome neuropsychological adverse effects of antiepileptic drugs? Expert Opin Pharmacother. 2017;18(6):551–554.
   PubMed Web of Science ®Google Scholar
• Krishnan V, Han MH, Graham DL, et al. Molecular adaptations underlying susceptibility and resistance to Social Defeat in Brain Reward Regions. Cell. 2007;131(2):391–404. doi: 10.1016/j.cell.2007.09.018
   PubMed Web of Science ®Google Scholar
• Friedman AK, Walsh JJ, Juarez B, et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Science. 2014;344(6181):313–319. doi: 10.1126/science.1249240
   PubMed Web of Science ®Google Scholar
• Friedman AK, Juarez B, Ku SM, et al. KCNQ channel openers reverse depressive symptoms via an active resilience mechanism. Nat Commun. 2016;7(1):11671. doi: 10.1038/ncomms11671
   PubMedGoogle Scholar
• Qin Y, Li H, Zhang Y, et al. Retigabine promotes ketamine’s antidepressant effect in the forced swim test in male and female C57BL/6J mice. Pharmacol Biochem Behav. 2023;230:173590. doi: 10.1016/j.pbb.2023.173590
   PubMed Web of Science ®Google Scholar
• Tan A, Costi S, Morris LS, et al. Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder. Mol Psychiatry. 2020;25(6):1323–1333. doi: 10.1038/s41380-018-0283-2
   PubMed Web of Science ®Google Scholar
• Costi S, Morris LS, Kirkwood KA, et al. Impact of the KCNQ2/3 channel Opener ezogabine on reward circuit activity and clinical symptoms in depression: results from a randomized controlled trial. Am J Psychiatry. 2021;178(5):437–446. doi: 10.1176/appi.ajp.2020.20050653
   PubMed Web of Science ®Google Scholar
• Perucca E, Brodie MJ, Kwan P, et al. 30 years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurol. 2020;19(6):544–556.
   PubMed Web of Science ®Google Scholar
• Sivapalarajah S, Krishnakumar M, Bickerstaffe H, et al. The prescribable drugs with efficacy in experimental epilepsies (PDE3) database for drug repurposing research in epilepsy. Epilepsia. 2018;59(2):492–501. doi: 10.1111/epi.13994
   PubMed Web of Science ®Google Scholar
• Snowball A, Chabrol E, Wykes RC, et al. Epilepsy gene therapy using an engineered potassium channel. J Neurosci. 2019;39(16):3159–3169. doi: 10.1523/JNEUROSCI.1143-18.2019
   PubMed Web of Science ®Google Scholar
• French JA, Bebin M, Dichter MA, et al. Antiepileptogenesis and disease modification: clinical and regulatory issues. Epilepsia Open. 2021;6(3):483–492. doi: 10.1002/epi4.12526
   PubMedGoogle Scholar
• Koepp MJ, Trinka E, Mah YH, et al. Antiepileptogenesis after stroke—trials and tribulations: methodological challenges and recruitment results of a phase II study with eslicarbazepine acetate. Epilepsia Open. 2023;8(3):1190–1201. doi: 10.1002/epi4.12735
   PubMedGoogle Scholar
• Nicolo JP, Chen Z, Moffat B, et al. Study protocol for a phase II randomised, double-blind, placebo-controlled trial of perampanel as an antiepileptogenic treatment following acute stroke. BMJ Open. 2021;11(5):e043488. doi: 10.1136/bmjopen-2020-043488
   PubMedGoogle Scholar